Check for updates

OPEN ACCESS

EDITED BY Nicole Horwood, University of East Anglia, United Kingdom

REVIEWED BY Qiusheng Si, Icahn School of Medicine at Mount Sinai, United States Xuekui Liu, Xuzhou Central Hospital, China Wenbin Chen, Shandong Provincial Hospital, China

*CORRESPONDENCE Xinhuan Zhang zhangxh22009@126.com Mingfeng Cao kathy0418@163.com

[†]These authors have contributed equally to this work

SPECIALTY SECTION

This article was submitted to Diabetes: Molecular Mechanisms, a section of the journal Frontiers in Endocrinology

RECEIVED 19 September 2022 ACCEPTED 16 November 2022 PUBLISHED 07 December 2022

CITATION

Lu K, Wang L, Fu Y, Li G, Zhang X and Cao M (2022) Bioinformatics analysis identifies immune-related gene signatures and subtypes in diabetic nephropathy. *Front. Endocrinol.* 13:1048139. doi: 10.3389/fendo.2022.1048139

COPYRIGHT

© 2022 Lu, Wang, Fu, Li, Zhang and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Bioinformatics analysis identifies immune-related gene signatures and subtypes in diabetic nephropathy

Kunna Lu^{1†}, Li Wang^{2†}, Yan Fu³, Guanghong Li¹, Xinhuan Zhang^{1*} and Mingfeng Cao^{1*}

¹Department of Endocrinology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China, ²Department of Pharmacy, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China, ³The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China

Background: Systemic inflammation and immune response are involved in the pathogenesis of diabetic nephropathy (DN). However, the specific immune-associated signature during DN development is unclear. Our study aimed to reveal the roles of immune-related genes during DN progression.

Methods: The GSE30529 and GSE30528 datasets were acquired from the Gene Expression Omnibus (GEO) database. Then, the intersection between differentially expressed genes (DEGs) and immune score-related genes (ISRGs) was screened. Subsequently, functional enrichment analyses were performed. The different immune phenotype-related subgroups were finally divided using unsupervised clustering. The core genes were identified by WGCNA and the protein-protein interaction (PPI) network. xCell algorithm was applied to assess the proportion of immune cell infiltration.

Results: 92 immune score-related DEGs (ISRDEGs) were identified, and these genes were enriched in inflammation- and immune-associated pathways. Furthermore, two distinct immune-associated subgroups (C1 and C2) were identified, and the C1 subgroup exhibited activated immune pathways and a higher percentage of immune cells compared to the C2 subgroup. Two core genes (LCK and HCK) were identified and all up-regulated in DN, and the expressions were verified using GSE30122, GSE142025, and GSE104954 datasets. GSEA indicated the core genes were mainly enriched in immune-related pathways. Correlation analysis indicated LCK and HCK expressions were positively correlated with aDC, CD4+ Tem, CD8+T cells, CD8+ Tem, and mast cells.

Conclusions: We identified two immune-related genes and two immuneassociated subgroups, which might help to design more precise tailored immunotherapy for DN patients.

KEYWORDS

diabetic kidney disease, bioinformatics, immune infiltration, xCell, GSEA

Introduction

Diabetes accounts for 30% to 50% of all chronic kidney disease cases, affecting 285 million people worldwide (1). Diabetic nephropathy (DN) induced by diabetes mellitus is the leading cause of end-stage kidney disease in both developing and developed countries (2). Microalbuminuria is one of the important indicators to evaluate the development of DN in clinical practice (3). Studies now indicated that not all diabetic patients with renal failure have massive proteinuria (4). It is not accurate to assess the prognosis or severity simply based on the degree of proteinuria (5). Besides, the current treatment strategies for DN are aimed at controlling blood pressure and blood glucose levels and suppressing the RAS system to slow DN development (6, 7). However, due to the individual heterogeneity of DN, not all patients could obtain effective treatment effects. Therefore, it is critical need to identify novel biomarkers and develop new methods for the early diagnosis and treatment of DN patients.

Given the morbidity and mortality associated with DN, many studies have sought to investigate the pathogenesis of DN and promote drug development aimed at showing or revering the DN progression. Previous studies revealed that renal fibrosis, activation of the renin-angiotensin-aldosterone system, oxidative stress, and inflammation are the major pathogenesis features of DN (8-10). Also, mitochondria dysfunction, autophagy, and innate immunity are implicated in the development of DN (11-13). The multiple signaling pathways are involved in the immune pathogenesis of DN (14). In diabetes, high blood sugar and high levels of lipids (including oxidized lipids, reactive oxygen species, and oxidative stress), cause the generation of damage-related molecular patterns, and then activate the inflammation-related pathways (15). In response to chronic activation of immune damage, podocytes, endothelial cells, and renal mesangial cells could generate all kinds of inflammatory factors, such as adhesion molecules, chemokines, and cytokines, which recruit macrophages and monocytes, and further initiate the proinflammatory cascades (16). A recent study showed that tissue-infiltrated immune cell populations play an important role in the pathogenesis of DN, including the specific contributions of leucocyte subsets (mast cells, lymphocytes, neutrophils, and macrophages) (17-19). Besides, the immune infiltration pattern was significantly changed in the glomerulus of DN (20). Furthermore, IDO1 was identified as a novel immune-related marker for DN patients and revealed to be involved in immune cell infiltrates in DN (21). Therefore, investigating the immune mechanisms of DN could provide novel insights into DN pathogenesis.

With the rapid development of genomics and bioinformatics, many disease databases have been established and improved, which provided a theoretical basis for exploring the new therapeutic targets and pathogenesis of diseases. Identification of immune cell infiltration-related differentially expressed genes *via* bioinformatics analysis could provide potential biomarkers for the diagnosis of DN and help us to better understand the pathogenesis of DN (22, 23). In this research, we aimed to identify immune-related genes (IRGs) that are implicated in the DN progression *via* a series of bioinformatics methods. Furthermore, unsupervised clustering was used to identify immune phenotype-associated subtypes in DN patients. Our findings will provide the theoretical basis for a better understanding of the immune response associated with DN development. The workflow of this study is presented in Figure 1.

Materials and methods

Collection of datasets

A total of five gene expression profile datasets, namely GSE30529, GSE30528, GSE104954, GSE142025, and GSE30122, were acquired from the Gene Expression Omnibus (GEO, available at: https://www.ncbi.nlm.nih.gov/geo/). The details for these datasets are presented in Table 1. Before data analysis, in order to remove possible outliers and make sure the accuracy of data, all gene expression profiles were standardized and normalized using limma R package (24). Two microarray datasets (GSE30529 and GSE30528) were merged and used as the training dataset. The surrogate variable analysis (SVA) algorithm was used to eliminate the batch effects (25).

A screen of immune score-related DEGs

First, we used the limma package of R to screen DEGs between the normal and DN groups (24). $|logFC| \ge 1$ and p.adj < 0.05 were the cutoff criteria for DEGs screen (26). The immune score of each sample was calculated by xCell algorithm (27). Besides, the training dataset of samples was divided into the high immune score and low immune score groups based on the median values of the immune score. Immune score-related genes (ISRGs) were screened between the two immune score-associated groups using the limma package of R. $|logFC| \ge 1$ and p.adj < 0.05 were the cutoff criteria for ISRGs identification. The ggplot and heatmap packages of R were used to visualize the analysis results. ISRDEGs were obtained by the intersection of DEGs and ISRGs.

Unsupervised clustering analysis

Based on the gene expression profiles of ISRDEGs, we further performed a consensus cluster analysis to identify distinct immune cell infiltration-related subgroups. In this study, the robustness and clustering number were evaluated by using a consensus clustering



algorithm (28). The "ConsensusClusterPlus" package of R was applied to perform 1000 iterations to ensure the robustness of the classification. The maximum cumulative distribution function (CDF) index was used as the optimal K value.

Weighted gene coexpression network analysis

WGCNA was used to establish potential modules associated with different subgroups of DN samples (29). The distance between each gene was calculated by the Pearson correlation coefficient, WGCNA package was applied to establish the correlation adjacency matrix. The hierarchical clustering analysis was performed using the "hclust" function, and the "pickSoftThreshold" function was applied to calculate the soft thresholding power value. Furthermore, the associated modules were constructed using the "blockwiseModules" function. The hub genes in the most relevant

TABLE 1 The microarray dataset information.

modules were identified based on Module Membership (MM) > 0.8 and Gene Significance (GS) > 0.6 (30).

Functional enrichment analysis and protein-protein interaction

A total of 1793 immune-related genes (IRGs) were collected from the InnateDB website (https://www.innatedb.com/ redirect.do?go=resourcesGeneLists). The clusterProfiler package of R was applied to perform the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) annotation enrichment analyses (31). For the top 10 significant GO and KEGG pathways, the ggplot2 R package of R was used to draw the bubble diagram. The Search Tool for the Retrieval of Interacting Genes (STRING) database (https://string-db.org/) was used to construct the PPI network, and the medium confidence > 0.4 was set to generate the TSV format file (32). Then, the PPI network was

Dataset ID	Platform	DN		Normal		Data type
		Туре	Number	Туре	Number	
GSE30528	GPL571	Glomeruli	9	Glomeruli	13	Training
GSE30529	GPL571	Tubuli	10	Tubuli	12	Training
GSE104954	GPL22945	Tubulointerstitium	7	Tubulointerstitium	18	Testing
GSE104954	GPL24120	Tubulointerstitium	10	Tubulointerstitium	3	Testing
GSE142025	GPL20301	Kidney biopsies	21	Kidney biopsies	9	Testing
GSE30122	GPL571	Glomerulus	19	Glomerulus	50	Testing

visualized by using Cytoscape software (version 3.7.2). Core genes were identified using the cytoHubba plug-in based on 10 algorithms (33).

Receiver operating characteristic curve analysis

ROC analysis was performed to further assess the predictive accuracy of core genes. The pROC package was applied to draw the ROC curves of core genes based on the gene expression profile.

Enrichment analysis

Gene set enrichment analysis (GSEA) is often used to analyze and interpret pathway-level changes between normal and disease groups (34). The "clusterProfiler", "enrichplot", "pathwork", and "DOSE" packages of R were applied to implement GSEA. The gene set of "h.all.v7.3.symbols" from the Molecular Signature Database was used as a reference gene set. P < 0.05 was considered a significant enrichment. Gene Set Variation analysis (GSVA) was also conducted by using the tidyverse R package and "C2.cp.all.v7.0.symbols" was used as the reference gene set.

Estimation of immune cell infiltrations in DN

xCell is a robust algorithm that analyzes the infiltration levels of 64 immune and stroma cell types, including extracellular matrix cells, epithelial cells, hematopoietic progenitors, innate and adaptive immune cells (27). The xCell algorithm was used to analyze the immune cell infiltrations between two subgroups. The correlation analysis between core genes and immune cell types was performed using the ggplot2 package of R.

Results

Screening for DEGs

As presented in Figure 2A, we identified a total of 266 DEGs between normal and DN groups, of which 202 genes were upregulated and 64 genes were down-regulated. The cluster heatmap of the DEGs was presented in Figure 2B.



and the red dots indicated the up-regulated genes. For the heatmap, the red group is the DN group, while the dark blue group is the normal group. The down-regulated genes are presented in blue, and up-regulated genes are presented in red.

Characterization of the immune cell infiltrations in DN and identification of ISRGs

xCell was applied to assess the differences in immune cell infiltrates between the DN and normal groups. As shown in Figure 3A, aDC, CD4+ memory T cells, CD4+ T cells, CD4+ Tem, CD8+ T cells, CD8+ Tcm, CD8+ Tem, cDC, iDC, macrophages, macrophages M1, macrophages M2, mast cells, memory B cells, NK cells, Tgd cells, Th2 cells, and immune score were significantly increased in the DN group, whereas CD8 +naïve T cells, pro B cells, and Tregs were significantly decreased in the DN group. The results indicated that immune cell patterns were significantly different between the normal and DN groups. Thus, two immune score-related subgroups were divided based on the median values of the immune score. As presented in Figure 3B, a total of 108 ISRGs were obtained between high immune score and low immune score subgroups. Among these genes, 78 genes were up-regulated, and 30 genes were down-regulated. The heatmap of the IRGs were presented in Figure 3C.

Functional enrichment analysis of ISRDEGs

The common genes (ISRDEGs) between DEGs and ISRGs were identified (Figure 4A). Based on the Venn result, a total of 92 ISRDEGs were used to perform the functional enrichment analysis. As shown in Figure 4B and Table S1. The results indicated that ISRDEGs were mainly enriched in the GO-biological process (BP) of leukocyte migration, regulation of lymphocyte activation, leukocyte cell-cell adhesion, tumor necrosis factor superfamily cytokine production, regulation of tumor necrosis factor superfamily cytokine production, etc. ISRDEGs were mainly enriched in GO-cell component (CC) of secretory granule lumen, immunological synapse, primary



between DN and normal groups. Volcano (B) and heatmap (C) plots of the ISRGs. For the volcano, the blue dots indicated the down-regulated genes and the red dots indicated the up-regulated genes. For the heatmap, the red group is the high immune score group, while the dark blue group is the low immune score group. The down-regulated genes are presented in blue, and up-regulated genes are presented in red.

lysosome, azurophil granule, etc. ISRDEGs were mainly enriched in GO-molecular function (MF) of heparin-binding, glycosaminoglycan binding, peptidase regulator activity, cytokine binding, C-C chemokine binding, etc. Besides, the results of KEGG enrichment analysis showed that the 92 ISRDEGs were significantly enriched in cytokine-cytokine receptor interaction, focal adhesion, chemokine signaling pathway, pertussis, natural killer cell medicated-cytotoxicity, NF-kappa B signaling pathway, Chagas disease, viral protein interaction with cytokine and cytokine receptor, and primary immunodeficiency (Figure 4C and Table S1).

Unsupervised cluster analysis identifies immune-associated gene subtypes

The unsupervised cluster analysis was applied to classify the DN patients with different immune phenotypes based on the expression of 92 ISRDEGs. We used the cophenetic correlation coefficients to determine the optimal k number, and our results showed that k = 2 was the optimal subtype number (Figures 5A–D). Two subtypes of DN samples were identified:

C1 with 12 samples, and C2 with 7 samples. As presented in Figures 5E, F, a total of 286 differential genes were obtained between C1 and C2 subgroups. Among these genes, 218 genes were up-regulated, and 68 genes were down-regulated. As shown in Figure 5G, the positive regulation of CD4 positive alpha beta T cell proliferation, T cell cytokine production, response to interferon beta, regulation of B cell proliferation, regulation of immunoglobulin production, T cell extravasation, B cell lineage commitment, and immunological memory process were activated in C1 subgroup, indicating that the C1 subgroup exhibited higher immune activation than the C2 subgroup.

Identification of key modules by WGCNA

As shown in Figures 6A, B, the soft-threshold power of β = 16 was selected, and the corresponding Pearson's correlation coefficient was calculated to construct a scale-free network. As shown in Figure 6C, 24 modules were identified, and bisque4 and skyblue modules exhibited the highest correlation with subgroups. Therefore, we selected the two modules for further analysis.



FIGURE 4

Functional enrichment analysis of ISRDEGs. (A) The Venn diagram shows the interaction between DEGs and ISRGs. GO (B) and KEGG (C) enrichment analyses for the 92 ISRDEGs.



Identification and functional enrichment analysis of IRGs in key modules

75 hub genes were identified in the two key modules (bisque4 and skyblue) based on MM > 0.8 and GS > 0.6. Among these hub genes, 24 IRGs were identified (Figures 7A, B). KEGG pathway analysis showed that these 24 IRGs were mainly enriched in natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, NF-kappa B signaling pathway, Rap1 signaling pathway, B cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, cytokine-cytokine receptor interaction, etc (Figure 7C). These 24 IRGs in BP were mainly involved in immune response-activating cell surface receptor signaling pathway, regulation of lymphocyte activation, T cell activation, leukocyte proliferation, T cell receptor signaling pathway, T cell proliferation, etc (Figure 7D). As for MF, 24 IRGs were mainly enriched in protein tyrosine kinase activity, cytokine binding, phosphoprotein binding, etc (Figure 7E). The CC analysis showed



that 24 IRGs were enriched in the membrane region, membrane microdomain, plasma membrane receptor complex, T cell receptor complex, etc (Figure 7F).

Identification and verification of core genes

Two core genes, namely, lymphocyte-specific protein tyrosine kinase (LCK) and hematopoietic cell kinase (HCK) were identified based on the overlapped parameters of the top 10 IRGs in 10 algorithms (Figure 8A). As shown in Figure 8B, the expression levels of LCK and HCK genes in the normal group were significantly lower than that of the DN group (p < 0.001). Besides, the diagnostic AUC values of LCK and HCK genes were 0.92 and 0.787, respectively (Figure 8C).

Furthermore, three independent microarray datasets (GSE30122, GSE142025, and GSE104954) were used for cross-validation. As shown in Figures 9A–C, the expression levels of LCK and HCK genes in the normal group were significantly

lower than that of the DN group (p < 0.01). Besides, the diagnostic value of core genes was verified by ROC analysis. For the GSE30122 cohort, the diagnostic AUC values of LCK and HCK genes were 0.886 and 0.724, respectively (Figure 9D). For the GSE104954 cohort, the diagnostic AUC values of LCK and HCK genes were 0.854 and 0.866, respectively (Figure 9E). For the GSE142025 cohort, diagnostic AUC values of LCK and HCK genes were 0.984 and 0.958, respectively (Figure 9F).

Single gene GSEA

We analyzed potential signaling pathways associated with core genes *via* GSEA. As shown in Figure 10A, type 1 diabetes mellitus (NES = -0.7254, p < 0.01), leishmania infection (ES = -0.7881, p < 0.01), intestinal immune network for IGA production (NES = -0.724, p = 0.002), chemokine signaling pathway (NES = -0.504, p < 0.001), B cell receptor signaling pathway (NES = -0.49, p = 0.004), primary immunodeficiency (NES = -0.7078, p = 0.009), leukocyte transendothelial migration



(NES = -0.4655, p = 0.002), T cell receptor signaling pathway (NES = -0.4783, p = 0.006), NOD-like receptor signaling pathway (NES = -0.5274, p = 0.01), and natural killer cell-mediated cytotoxicity (NES = -0.4878, p = 0.003) were mainly enriched in the HCK high-expressed phenotype.

As shown in Figure 10B, leukocyte transendothelial migration (NES = -0.5069, p < 0.001), chemokine signaling pathway (NES = -0.4971, p < 0.001), NOD-like receptor signaling pathway (NES = -0.5482, p = 0.01), primary immunodeficiency (NES = -0.7069, p = 0.006), T cell receptor signaling pathway (NES = -0.4884, p = 0.004), intestinal immune network for IGA production (NES = -0.724, p = 0.002), natural killer cell-mediated cytotoxicity (NES = -0.4914, p = 0.0038), Type 1 diabetes mellitus (NES = -0.6312, p = 0.019), B cell receptor signaling pathway (NES = -0.4268, p = 0.023), and

apoptosis (ES = -0.3467, p = 0.016) were mainly enriched in the LCK high-expressed phenotype. These results revealed that the two core genes were all linked to the immune responses.

Immune cell infiltration analysis

xCell was applied to assess the differences in immune cell infiltrates between the C1 and C2 subgroups. As shown in Figure 11A, aDC, B cells, CD4+ Tem, CD8+ T cells, CD8+ Tcm, CD8+ Tem, cDC, dendritic cells (DC), iDC, mast cells, and immune score were significantly increased in the C1 subgroup. As shown in Figure 11B, the expression levels of LCK and HCK genes in the C1 subgroup were significantly higher than that of the C2 subgroup (p < 0.01). Besides, correlation analysis showed



that LCK and HCK were positively correlated with aDC, CD4+ Tem, CD8+ T cells, CD8+ Tem, CD8+ Tcm, and mast cells (Figure 11C).

Discussion

DN is one of the common microvascular complications of type 2 diabetes mellitus and occurs in up to 20-50% of patients with diabetes (35). DN imposes a huge burden on national health systems due to its high expenditure and high incidence. Therefore, there is an urgent need to develop promising clinical biomarkers of early DN that can effectively slow the progression of DN. DN represents a chronic inflammatory disease that leads to renal function disorder, albuminuria, and podocyte injury (11). Recent studies have revealed that inflammation and immune pathways play important roles in DN progression, and the identification of novel immune-related signatures may link to the development of novel therapeutic strategies (8, 19, 36). Thus, it is important to develop novel immune-associated signatures for the diagnosis and treatment of DN.

In our study, we identified 92 ISRDEGs in the expression profiles of 25 normal samples and 19 DN samples using a series of bioinformatics analyses. The subsequent KEGG and BP functional enrichment analyses indicated that these ISRDEGs were enriched in leukocyte migration, regulation of lymphocyte activation, humoral immune response, leukocyte cell-cell adhesion, tumor necrosis factor superfamily cytokine production, cytokine-cytokine receptor interaction, chemokine signaling pathway, natural killer cell mediated cytotoxicity, NFkappa B signaling pathway, and primary immunodeficiency. Consistent with our findings, activated leukocytes play an important role in the pathogenesis of DN (37). Cytokine and cytokine receptors have been reported to play a key role in



macrophage/monocyte recruitment in animal models of DN, as well as associated with the progression of interstitial inflammation of DN (38, 39).

Based on the result of WGCNA, two IRGs (LCK and HCK) were identified as core biomarkers associated with immune response in DN. All of them could predict the progression of DN in multiple GEO datasets. LCK is a vital activator of T cells, which plays an important role in several cellular processes such as cell differentiation, cell proliferation, cell adhesion, and cell cycle (40, 41). LCK is related to the CD8 and CD4 co-receptors and contributes to signaling via T cell receptor complex (42). Since LCK plays a vital role in T cell signaling and cytokine production, alteration in activity or expression of LCK may be involved in various disease progressions, including atherosclerosis, ulcerative colitis, psoriasis, rheumatoid arthritis, diabetes, asthma, and cancer (41). LCK is involved in the progress of leptin-induced renal inflammation during aging (43). A recent study revealed that the G allele of SNP rs10914542 of LCK inhibits the TCR/CD3-mediated T cell activation and increases the risk of type 1 diabetes in children (44). It has been reported that β ig-h3 inhibits T cell activation in type 1 diabetes via suppression of LCK (45). HCK transmits various extracellular signals and involves in cell migration, cell differentiation, and cell proliferation (46). Activation of the NLRP3 inflammasome may involve the development of DN (47). HCK is essential for the activation of NLRP3

inflammasome *in vivo* (48). The previous study revealed that HCK is an important Src kinase family member that participated in the progression of renal fibrosis (49). HCK plays a vital role in the macrophage activation and the secretion of TNF- α , which leads to the progression of diabetes (50). However, there were few reports on the role of LCK and HCK in DN progression. In the present study, for the first time, our findings showed that LCK and HCK were significantly up-regulated in DN and could act as an effectively diagnostic biomarker for DN patients.

Importantly, LCK and HCK were also found to be positively correlated with immune cell infiltrations in DN progression. Recent studies revealed that DN is a chronic inflammatory disease, and immune cells associated with adaptive and innate immune responses, including mast cells, neutrophils, T cells, B cells, DC, and macrophage, might be implicated in DN development (51). Since the immune-associated pathways (positive regulation of CD4 positive alpha beta T cell proliferation, T cell cytokine production, regulation of B cell proliferation, regulation of immunoglobulin production, T cell extravasation, B cell lineage commitment, and immunological memory process) were activated in the C1 subgroup, the relationship between DN subgroups and immune cells was further investigated. We found that the aDC, B cells, CD4+ Tem, CD8+ T cells, CD8+ Tcm, CD8+ Tem, cDC, DC, iDC, mast cells, and immune score were significantly expressed in the C1 subgroup compared with the



C2 subgroup. The previous study has reported that aberrant recruitment and activation of T cells in the interstitium are the potential pathological mechanisms of DN (52). B cells also contributed to the progression of diabetic kidney disease (53). Mast cells could promote renal fibrosis and inflammation, and thus implicated in the pathogenesis of DN (54, 55). A recent

study reported that DC plays an important role in the pathogenesis of DN (56). Therefore, we speculated the C1 subgroup is more likely to develop advanced DN than the C2 subgroup.

However, there are several limitations in our study. First, larger clinical sample sizes are needed to verify the expression of key genes.



Second, DN-related animal models should be established to verify the role of immune-related genes on disease progression.

Conclusion

In conclusion, we identified two core genes (LCK and HCK) as diagnostic biomarkers for the diagnosis and immunotherapy of DN patients. Furthermore, we proposed a novel molecular classification containing non-immune and immune subgroups in DN patients. Collectively, our findings could help to design more precise tailored immunotherapy for ND patients.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Author contributions

KL and LW wrote the manuscript and designed the study. YF, GL and MC analyzed the data. XZ reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

Funding

The study was supported by the Natural Science Foundation of Shandong Province of China (Grant No. ZR2017LH023); Higher Educational Science and Technology Program of Shandong Province, China (Grant No. J17KA246); Shandong Provincial Key Laboratory of Endocrinology and Lipid Metabolism (Grant No. SDkeylab-Endo&LiMe2019-01); Medical and Health Project of Shandong Province, China (Grant No. 2015WS0096) as well as Academic Promotion Program of Shandong First Medical University (Grant No. 2019QL017).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet (2017) 389(10075):1238-52. doi: 10.1016/S0140-6736(16)32064-5

2. Umanath K, Lewis JB. Update on diabetic nephropathy: Core curriculum 2018. Am J Kidney Dis (2018) 71(6):884–95. doi: 10.1053/j.ajkd.2017.10.026

3. Mandelbrot DA, Reese PP, Garg N, Thomas CP, Rodrigue JR, Schinstock C, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline on the evaluation and care of living kidney donors. *Am J Kidney Dis* (2020) 75(3):299–316. doi: 10.1053/j.ajkd.2019.10.005

4. Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. *J Diabetes Investig* (2017) 8(1):6–18. doi: 10.1111/jdi.12533

5. Qi C, Mao X, Zhang Z, Wu H. Classification and differential diagnosis of diabetic nephropathy. J Diabetes Res (2017) 2017:8637138. doi: 10.1155/2017/8637138

6. Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, et al. Effects of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: A systematic review and meta-analysis. *Kidney Blood Press Res* (2018) 43(3):768– 79. doi: 10.1159/000489913

 Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodiumglucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. *Bmj* (2021) 372:m4573. doi: 10.1136/bmj.m4573

8. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) (2013) 124(3):139-52. doi: 10.1042/CS20120198

9. Hussain Lodhi A, Ahmad FU, Furwa K, Madni A. Role of oxidative stress and reduced endogenous hydrogen sulfide in diabetic nephropathy. *Drug Des Devel Ther* (2021) 15:1031–43. doi: 10.2147/DDDT.S291591

10. Calle P, Hotter G. Macrophage phenotype and fibrosis in diabetic nephropathy. Int J Mol Sci (2020) 21(8):2806. doi: 10.3390/ijms21082806

11. Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol (2016) 12(1):13-26. doi: 10.1038/nrneph.2015.175

12. Koch EAT, Nakhoul R, Nakhoul F, Nakhoul N. Autophagy in diabetic nephropathy: A review. *Int Urol Nephrol* (2020) 52(9):1705-12. doi: 10.1007/s11255-020-02545-4

13. Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. *Nat Rev Nephrol* (2018) 14(5):291–312. doi: 10.1038/nrneph.2018.9

14. Chen J, Liu Q, He J, Li Y. Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target. *Front Immunol* (2022) 13:958790. doi: 10.3389/fimmu.2022.958790

15. Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. *Annu Rev Pathol* (2011) 6:395–423. doi: 10.1146/annurev.pathol.4.110807.092150

16. Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol (2020) 16(4):206–22. doi: 10.1038/s41581-019-0234-4

17. Tesch GH. Diabetic nephropathy - is this an immune disorder? *Clin Sci* (*Lond*) (2017) 131(16):2183–99. doi: 10.1042/CS20160636

18. Wilson PC, Wu H, Kirita Y, Uchimura K, Ledru N, Rennke HG, et al. The single-cell transcriptomic landscape of early human diabetic nephropathy. *Proc Natl Acad Sci USA* (2019) 116(39):19619–25. doi: 10.1073/pnas.1908706116

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fendo.2022.1048139/full#supplementary-material

19. Zheng Z, Zheng F. Immune cells and inflammation in diabetic nephropathy. *J Diabetes Res* (2016) 2016:1841690. doi: 10.1155/2016/1841690

20. Zhou W, Liu Y, Hu Q, Zhou J, Lin H. The landscape of immune cell infiltration in the glomerulus of diabetic nephropathy: Evidence based on bioinformatics. *BMC Nephrol* (2022) 23(1):303. doi: 10.1186/s12882-022-02906-4

21. Yu K, Li D, Xu F, Guo H, Feng F, Ding Y, et al. IDO1 as a new immune biomarker for diabetic nephropathy and its correlation with immune cell infiltration. *Int Immunopharmacol* (2021) 94:107446. doi: 10.1016/j.intimp.2021.107446

22. Jia Y, Xu H, Yu Q, Tan L, Xiong Z. Identification and verification of vascular cell adhesion protein 1 as an immune-related hub gene associated with the tubulointerstitial injury in diabetic kidney disease. *Bioengineered* (2021) 12 (1):6655–73. doi: 10.1080/21655979.2021.1976540

23. Wang Y, Zhao M, Zhang Y. Identification of fibronectin 1 (FN1) and complement component 3 (C3) as immune infiltration-related biomarkers for diabetic nephropathy using integrated bioinformatic analysis. *Bioengineered* (2021) 12(1):5386–401. doi: 10.1080/21655979.2021.1960766

24. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* (2015) 43(7):e47. doi: 10.1093/nar/gkv007

25. Parker HS, Leek JT, Favorov AV, Considine M, Xia X, Chavan S, et al. Preserving biological heterogeneity with a permuted surrogate variable analysis for genomics batch correction. *Bioinformatics* (2014) 30(19):2757–63. doi: 10.1093/bioinformatics/btu375

26. Sohrabi E, Rezaie E, Heiat M, Sefidi-Heris Y. An integrated data analysis of mRNA, miRNA and signaling pathways in pancreatic cancer. *Biochem Genet* (2021) 59(5):1326–58. doi: 10.1007/s10528-021-10062-x

27. Aran D. Cell-type enrichment analysis of bulk transcriptomes using xCell. Methods Mol Biol (2020) 2120:263–76. doi: 10.1007/978-1-0716-0327-7_19

28. Markovich Gordon M, Moser AM, Rubin E. Unsupervised analysis of classical biomedical markers: Robustness and medical relevance of patient clustering using bioinformatics tools. *PLoS One* (2012) 7(3):e29578. doi: 10.1371/journal.pone.0029578

29. Langfelder P, Horvath S. WGCNA: An r package for weighted correlation network analysis. *BMC Bioinf* (2008) 9:559. doi: 10.1186/1471-2105-9-559

30. Quan Q, Xiong X, Wu S, Yu M. Identification of immune-related key genes in ovarian cancer based on WGCNA. *Front Genet* (2021) 12:760225. doi: 10.3389/ fgene.2021.760225

31. Yu G, Wang LG, Han Y, He QY. clusterProfiler: An r package for comparing biological themes among gene clusters. *Omics* (2012) 16(5):284–7. doi: 10.1089/omi.2011.0118

32. Wang J, Wang Y, Kong F, Han R, Song W, Chen D, et al. Identification of a six-gene prognostic signature for oral squamous cell carcinoma. *J Cell Physiol* (2020) 235(3):3056–68. doi: 10.1002/jcp.29210

33. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: Identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* (2014) 8(Suppl 4):S11. doi: 10.1186/1752-0509-8-S4-S11

34. Powers RK, Goodspeed A, Pielke-Lombardo H, Tan AC, Costello JC. GSEA-InContext: identifying novel and common patterns in expression experiments. *Bioinformatics* (2018) 34(13):i555–64. doi: 10.1093/bioinformatics/bty271 35. Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. *Diabetes Obes Metab* (2020) 22(Suppl 1):3–15. doi: 10.1111/dom.14007

36. Yao X, Shen H, Cao F, He H, Li B, Zhang H, et al. Bioinformatics analysis reveals crosstalk among platelets, immune cells, and the glomerulus that may play an important role in the development of diabetic nephropathy. *Front Med* (2021) 8:657918. doi: 10.3389/fmed.2021.657918

37. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol JASN (2006) 17(2):368–77. doi: 10.1681/ASN.2005080859

38. Araújo LS, Torquato BGS, da Silva CA, Dos Reis Monteiro MLG, Dos Santos Martins ALM, da Silva MV, et al. Renal expression of cytokines and chemokines in diabetic nephropathy. *BMC Nephrol* (2020) 21(1):308. doi: 10.1186/s12882-020-01960-0

39. Chang TT, Chen JW. The role of chemokines and chemokine receptors in diabetic nephropathy. *Int J Mol Sci* (2020) 21(9):3172. doi: 10.3390/ijms21093172

40. Rohrs JA, Wang P, Finley SD. Predictive model of lymphocyte-specific protein tyrosine kinase (LCK) autoregulation. *Cell Mol Bioeng* (2016) 9:351–67. doi: 10.1007/s12195-016-0438-7

41. Kumar Singh P, Kashyap A, Silakari O. Exploration of the therapeutic aspects of lck: A kinase target in inflammatory mediated pathological conditions. *BioMed Pharmacother* (2018) 108:1565-71. doi: 10.1016/j.biopha.2018.10.002

42. Shebzukhov YV, Stanislawiak S, Bezhaeva TR, Nedospasov SA, Kuprash DV. Low level of lck kinase in Th2 cells limits expression of CD4 co-receptor and S73 phosphorylation of transcription factor c-jun. *Sci Rep* (2017) 7(1):2339. doi: 10.1038/s41598-017-02553-y

43. Kim DH, Park JW, Jeong HO, Lee B, Chung KW, Lee Y, et al. Novel role of lck in leptin-induced inflammation and implications for renal aging. *Aging Dis* (2019) 10(6):1174–86. doi: 10.14336/AD.2019.0218

44. Zhu Q, Wang J, Zhang L, Bian W, Lin M, Xu X, et al. LCK rs10914542-G allele associates with type 1 diabetes in children *Via* T cell hyporesponsiveness. *Pediatr Res* (2019) 86(3):311–5. doi: 10.1038/s41390-019-0436-2

45. Patry M, Teinturier R, Goehrig D, Zetu C, Ripoche D, Kim IS, et al. β ig-h3 represses T-cell activation in type 1 diabetes. *Diabetes* (2015) 64(12):4212–9. doi: 10.2337/db15-0638

46. Ernst M, Inglese M, Scholz GM, Harder KW, Clay FJ, Bozinovski S, et al. Constitutive activation of the SRC family kinase hck results in spontaneous pulmonary inflammation and an enhanced innate immune response. *J Exp Med* (2002) 196(5):589–604. doi: 10.1084/jem.20020873

47. Wu M, Yang Z, Zhang C, Shi Y, Han W, Song S, et al. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy. *Metabolism* (2021) 118:154748. doi: 10.1016/j.metabol.2021.154748

48. Kong X, Liao Y, Zhou L, Zhang Y, Cheng J, Yuan Z, et al. Hematopoietic cell kinase (HCK) is essential for NLRP3 inflammasome activation and lipopolysaccharide-induced inflammatory response *In vivo. Front Pharmacol* (2020) 11:581011. doi: 10.3389/fphar.2020.581011

49. Wei C, Li L, Menon MC, Zhang W, Fu J, Kidd B, et al. Genomic analysis of kidney allograft injury identifies hematopoietic cell kinase as a key driver of renal fibrosis. *J Am Soc Nephrol* (2017) 28(5):1385–93. doi: 10.1681/ASN.2016020238

50. Choi KS, Jun HS, Kim HN, Park HJ, Eom YW, Noh HL, et al. Role of hck in the pathogenesis of encephalomyocarditis virus-induced diabetes in mice. *J Virol* (2001) 75(4):1949–57. doi: 10.1128/JVI.75.4.1949-1957.2001

51. Yang X, Mou S. Role of immune cells in diabetic kidney disease. Curr Gene Ther (2017) 17(6):424-33. doi: 10.2174/1566523218666180214100351

52. Moon JY, Jeong KH, Lee TW, Ihm CG, Lim SJ, Lee SH. Aberrant recruitment and activation of T cells in diabetic nephropathy. *Am J Nephrol* (2012) 35(2):164–74. doi: 10.1159/000334928

53. Smith MJ, Simmons KM, Cambier JC. B cells in type 1 diabetes mellitus and diabetic kidney disease. *Nat Rev Nephrol* (2017) 13(11):712–20. doi: 10.1038/ nrneph.2017.138

54. de Morais RB, do Couto Muniz VP, Nunes Costa E, Filho SRF, Nakamura Hiraki KR, Bispo-da-Silva LB, et al. Mast cell population in the development of diabetic nephropathy: Effects of renin angiotensin system inhibition. *Biomedicine pharmacotherapy = Biomedecine pharmacotherapie* (2018) 107:1115–8. doi: 10.1016/j.biopha.2018.08.066

55. Zheng JM, Yao GH, Cheng Z, Wang R, Liu ZH. Pathogenic role of mast cells in the development of diabetic nephropathy: A study of patients at different stages of the disease. *Diabetologia* (2012) 55(3):801–11. doi: 10.1007/s00125-011-2391-2

56. Kim H, Kim M, Lee HY, Park HY, Jhun H, Kim S. Role of dendritic cell in diabetic nephropathy. Int J Mol Sci (2021) 22(14):7554. doi: 10.3390/ijms22147554